Drug Type Bispecific antibody |
Synonyms PMC-201 |
Target |
Action inhibitors, antagonists |
Mechanism DLL4 inhibitors(Delta-like protein 4 inhibitors), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | South Korea | 14 Jan 2019 | |
| Solid tumor | Preclinical | South Korea | - |






